window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

narcolepsy type 1

  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Takeda’s oveporexton FDA decision tops GlobalData’s Q3 2026 biopharma catalysts

    GlobalData has identified Takeda’s oveporexton FDA decision as one of [...]

    June 25, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Kayentis launches AI-powered eConsent tool for clinical trials
    Categories: Clinical & Regulatory, Digital & Data
  • Orphan Therapeutics Accelerator expands rare disease development network to advance ultra-rare therapies
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
  • Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top